Description
-
Randomised, stratified, open-label, active-controlled study
-
2 treatment conditions
-
FF/UMEC/VI (trelegy ellipta)
-
Comparator ICS/LABA
-
Trial length
12 months
Participant age
Participant ages can range from 18-75
Patient eligibility
-
Participants must have a prior diagnosis of asthma
-
Participants must NOT have more than 1 severe exacerbation of asthma within the past 12 months
-
Participants current medications CANNOT include RELVAR ELLIPTA and ARNUITY ELLIPTA
-
Female participants must NOT be pregnant
-
Female participants must NOT be breastfeeding
4 onsite visits and 1 scheduled phone call is required from participants
*Travel is reimbursed for each visit
Follow-up inclusions
Objectives
To evaluate the effects of fluticasone furoate/umeclidinium bromide/vilanterol trifenatate (FF/UMEC/VI) on lung function compared with inhaled corticosteroids/long-acting beta-2 agonists (ICS/LABA).
Description
-
Randomised, stratified, open-label, active-controlled study
-
2 treatment conditions (FF/UMEC/VI versus ICS/LABA)
-
Participants randomised into 1 of the 2 treatment conditions
Trial length
12 months
Participant age
Participant ages can range from 18-75
Patient eligibility
-
Participants must have a prior diagnosis of asthma
-
Participants must NOT have more than 1 severe exacerbation of asthma within the past 12 months
-
Participants current medications CANNOT include RELVAR ELLIPTA and ARNUITY ELLIPTA
-
Female participants must NOT be pregnant
-
Female participants must NOT be breastfeeding
4 onsite visits and 1 scheduled phone call is required from participants
*Travel is reimbursed for each visit
Follow-up inclusions
Objectives
To evaluate the effects of fluticasone furoate/umeclidinium bromide/vilanterol trifenatate (FF/UMEC/VI) on lung function compared with inhaled corticosteroids/long-acting beta-2 agonists (ICS/LABA).
Get in touch with us
Our friendly team would love to hear from you!